Opinion|Videos|May 30, 2024
Patient-Centered Approach: Adapting Narcolepsy Treatments to Address Adverse Events and Mitigate Misuse Risks
The panel offers comprehensive insights on adapting narcolepsy treatments for patients who experience adverse effects, achieve partial response, or have a history of substance abuse.
Advertisement
Episodes in this series
Advertisement
Related to this article
Lisa Harding, MD, urges psychiatrists to gather histories, deprescribe safely, and send focused sleep referrals now that orexin agonists have arrived for narcolepsy.
Once-monthly subcutaneous olanzapine TEV-749 shows sustained stabilization and remission in schizophrenia, supports direct switching, and avoids post-injection monitoring.
Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
Explore PTSD prevalence, comorbidities, and first-line care as we invite clinicians to share cases and research.
Veterans younger than 30 starting antidepressants, and anyone coprescribed opioids and benzodiazepines, will need to sign consent forms starting in 2027.
How genes and early stress interact to shape antisocial behavior, from dopamine and serotonin pathways to MAOA and oxytocin findings.
Policy shifts have opened the door to telehealth buprenorphine for pregnant and postpartum women with OUD, but research, guidelines, and state policy lag behind.
Overlooking how hearing loss and sign language shape the Mental Status Examination can make language deprivation look like psychosis, authors warn.
Advertisement
Advertisement
Trending on Psychiatric Times
1
What Clinicians Need to Know About Postpartum Psychosis
2
Brain Trust: Therapeutic Drug Monitoring and Adherence in Schizophrenia, With Jonathan M. Meyer, MD
3
Nature vs Nurture: The Interplay Between Genetics and Environmental Influences
4
Reframing Long-Acting Injectable Antipsychotics as a Path to Patient Autonomy
5